A new article published in the European Annals of Allergy and Clinical Immunology discussed that atopic dermatitis (AD) is a complex disease with host and environmental factors underlying its pathology. Its treatment is multidimensional reflecting the diverse nature of its triggers, which include emollients, topical steroids and calcineurin inhibitors among others. Immunological dysfunction can be addressed broadly with systemic immunosupressors and specifically with monoclonal antibodies. Dupilumab, which targets IL-4 and IL-13, was granted approval for the management of moderate-to-severe AD. Besides, biologics targeting IgE/Th2 pathways may have its role in patients with overlapping AD and asthma. The authors stated that psychological distress can exacerbate symptoms of AD and is associated with an increased severity of AD. Prevention of exacerbations in AD patients is essential and environmental triggers, such as, allergens can be addressed in selected cases with allergic immunotherapy.